Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019
Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021
In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection, are recently infected, and who have mild or no symptoms. This pilot study being conducted in Mexico will evaluate both the magnitude and duration of viral load reduction after a single dose of OPN-019. The Company expects top-line results from this study in second quarter 2021.
The company shows stable revenue growth from year to year.
Technical analysis:
From May 2020 to the end of June 2020, the 5th wave movement was completed.After that, a correction began.
At the moment, the company's shares are in the oversold zone according to the RSI indicator.
The company has several open gaps, namely in the following areas: $ 6-7, $ 10-11 per share.
At the moment, the company's shares are at a strong support level .
Disclosure: I am/we are long OPTN.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from TradingView). I have no business relationship with any company whose stock is mentioned in this article.